title: Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.
abstract: The development of proteasome inhibitors (PIs) and immunomodulatory drugs has significantly improved outcomes for patients with relapsed/refractory multiple myeloma (RRMM); however, not all patients benefit from treatment with these agents and some patients can become drug refractory over time. Due to the largely incurable nature of multiple myeloma, the development of newer agents is ongoing and includes new oral PIs (ixazomib), immunotherapies (e.g., CD38- or SLAMF7-targeted antibodies), and small molecules. This review provides an overview of the advances in targeted therapy for patients with RRMM, including recently approved agents, with a focus on monotherapy and combined targeted therapies.
authors.affiliation: a Hematology Department , CHU Cochin, Paris V René Descartes University , Paris , France.
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Le Ray
authors.affiliation: b Tisch Cancer Institute/Multiple Myeloma Program , Mount Sinai Medical Center , New York , NY , USA.
authors.forename: Sundar
authors.initials: S
authors.lastname: Jagannath
authors.affiliation: c Department of Haematology , University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino , Torino , Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Palumbo
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D009364:Neoplasm Recurrence, Local; D061988:Proteasome Inhibitors / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D061988:Proteasome Inhibitors
keywords: combination therapy; immunomodulatory drugs; monotherapy; proteasome inhibitors; relapsed/refractory multiple myeloma